| N02BG07 |
N02BG07 flupirtine |
| N02BG08 |
N02BG08 ziconotide |
| N02BG09 |
N02BG09 methoxyflurane |
| N02BG10 |
N02BG10 cannabinoids |
| N02C |
N02C Antimigraine preparations |
| N02CA |
N02CA Ergot alkaloids |
| N02CA01 |
N02CA01 dihydroergotamine |
| N02CA02 |
N02CA02 ergotamine |
| N02CA04 |
N02CA04 methysergide |
| N02CA07 |
N02CA07 lisuride |
| N02CA51 |
N02CA51 dihydroergotamine, combinations |
| N02CA52 |
N02CA52 ergotamine, combinations excl. psycholeptics |
| N02CA72 |
N02CA72 ergotamine, combinations with psycholeptics |
| N02CB |
N02CB Corticosteroid Derivatives |
| N02CB01 |
N02CB01 Flumedroxone |
| N02CC |
N02CC Selective serotonin (5-HT1) agonists |
| N02CC01 |
N02CC01 sumatriptan |
| N02CC02 |
N02CC02 naratriptan |
| N02CC03 |
N02CC03 zolmitriptan |
| N02CC04 |
N02CC04 rizatriptan |
| N02CC05 |
N02CC05 almotriptan |
| N02CC06 |
N02CC06 Eletriptan |
| N02CC07 |
N02CC07 frovatriptan |
| N02CD |
N02CD Calcitonin Gene-Related Peptide (CGRP) Antagonists |
| N02CD01 |
N02CD01 Erenumab |
| N02CD02 |
N02CD02 Galcanezumab |
| N02CD03 |
N02CD03 Fremanezumab |
| N02CX |
N02CX Other antimigraine preparations |
| N02CX01 |
N02CX01 pizotifen |
| N02CX02 |
N02CX02 clonidine |